GSK plans to sell off remaining stake in consumer spinout Haleon

British drug­mak­er GSK will sell off the rest of its share in Ha­le­on af­ter slow­ly sell­ing off multi­bil­lion-dol­lar pieces of its own­er­ship in the con­sumer com­pa­ny.

The sale of the fi­nal 4.2% stake in Ha­le­on, which was cre­at­ed in 2019 by merg­ing Pfiz­er and GSK’s con­sumer health busi­ness­es, caps a string of sales since last year. When the com­pa­ny was spun off in 2022, GSK re­tained about 13% of Ha­le­on’s shares, the phar­ma ma­jor said in a fil­ing Thurs­day. But it sold chunks of its stake last May and in Jan­u­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.